Form 8-K - Current report:
SEC Accession No. 0001193125-25-274220
Filing Date
2025-11-10
Accepted
2025-11-10 16:08:28
Documents
12
Period of Report
2025-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K annx-20251110.htm   iXBRL 8-K 65299
2 EX-99.1 annx-ex99_1.htm EX-99.1 223921
3 GRAPHIC img193911374_0.jpg GRAPHIC 14203
  Complete submission text file 0001193125-25-274220.txt   436682

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT annx-20251110.xsd EX-101.SCH 28075
14 EXTRACTED XBRL INSTANCE DOCUMENT annx-20251110_htm.xml XML 4888
Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650) 822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

EIN.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39402 | Film No.: 251466225
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)